athenahealth (ATHN) & Complete Genomics (GNOM) Head to Head Review

athenahealth (NASDAQ: ATHN) and Complete Genomics (NASDAQ:GNOM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares athenahealth and Complete Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
athenahealth 2.65% 6.78% 3.83%
Complete Genomics N/A N/A N/A

Earnings & Valuation

This table compares athenahealth and Complete Genomics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
athenahealth $1.08 billion 4.78 $21.00 million $0.77 168.14
Complete Genomics N/A N/A N/A ($2.35) -1.34

athenahealth has higher revenue and earnings than Complete Genomics. Complete Genomics is trading at a lower price-to-earnings ratio than athenahealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for athenahealth and Complete Genomics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
athenahealth 1 15 8 0 2.29
Complete Genomics 0 0 0 0 N/A

athenahealth currently has a consensus target price of $142.55, indicating a potential upside of 10.10%. Given athenahealth’s higher probable upside, equities analysts clearly believe athenahealth is more favorable than Complete Genomics.

Summary

athenahealth beats Complete Genomics on 8 of the 8 factors compared between the two stocks.

About athenahealth

athenahealth, Inc. provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet. The Company has a range of network-enabled services to support healthcare providers across the continuum of care. The Company offers various combinations of its services to its clients, including athenaOne and athenaOne for Hospitals and Health Systems, depending on whether they are medical groups and practices or hospitals and larger health systems. As of December 31, 2016, the Company connected care across a national network of approximately 88,000 providers and approximately 86 million patients. Its suite of network-enabled services includes athenaCollector, athenaClinicals, athenaCommunicator, athenaCoordinator, Population Health and Epocrates.

About Complete Genomics

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Receive News & Ratings for athenahealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply